An Act relative to promoting comprehensive transparency in the pharmaceutical industry

This bill amends Massachusetts state law to increase transparency within the pharmaceutical industry by adding new definitions for key industry players. It specifically defines "pharmaceutical manufacturing companies," "pharmacy benefit managers," "pipeline drugs," and "sponsors" to clarify who must comply with reporting requirements. The legislation also expands the group of entities responsible for paying fees to the state commission, ensuring that costs for analyzing drug spending trends are fully covered by these companies and managers. By updating existing statutes, the bill aims to improve data collection on pharmaceutical expenditures without introducing new regulatory mandates beyond these definitional and fee-related changes.